Dosage May Increase Gradually Treatment plans often begin with lower doses that are increased over time
Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid GLP-1 medications
It also plays a crucial role in the production of endothelium-derived relaxing factor (EDRF) , primarily nitric oxide
In light of the narrow therapeutic window defined by the balance between glucose-lowering efficacy and (so-called) gastrointestinal side effects, it seems unlikely that future long-acting GLP-1 receptor agonists will provide substantially greater efficacy without inducing more side effects compared with the already available compounds
Common side effects such as nausea, vomiting, and gastrointestinal discomfort can deter patient adherence, especially during the early stages of treatment
Semaglutide is a synthetic version of a natural hormone called glucagon-like peptide-1, or GLP-1